Abraham Morgentaler, MD, reviews evidence showing no association between testosterone therapy and prostate cancer risk and explains the saturation model of androgen action.
|Articles|August 20, 2019
Dr. Frydenberg discusses MRI’s potential as a screening tool
Mark Frydenberg, MD, of Australia's Monash University, discusses whether multiparametric MRI is ready to be used as a screening modality for prostate cancer.
Advertisement
Is multiparametric MRI at a point where urologists could use it as a screening modality for prostate cancer? In this interview, Mark Frydenberg, MD, of Monash University in Melbourne, Victoria, Australia, addresses this question and how the use of MRI is changing.
Advertisement
Related to this article
Based on these results, the trial protocol has been amended to move enrollment earlier in the course of disease progression.
An analysis of NRG/RTOG 0815 found Decipher predicted distant metastasis risk and identified patients with greater benefit from short-term ADT.
Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
The phase 3 BiPASS trial is evaluating the use of 68Ga-PSMA-PET in combination with MRI for pre-biopsy prostate cancer detection.
In RTOG 3506, adding enzalutamide to standard ADT and salvage radiotherapy was associated with 2-year PFS benefit.
In the phase 3 PACE-A trial, SBRT and prostatectomy showed similar 8-year disease control in localized prostate cancer, with lower rates of urinary incontinence after SBRT.
Advertisement
Advertisement
Trending on Urology Times
1
Avoiding False Positives on Prostate Cancer PSMA PET Scans
2
Experts review evidence on testosterone and prostate cancer
3
Carotuximab plus apalutamide shows interim PFS benefit in mCRPC
4
Aglatimagene besadenovec shows sustained immune remodeling in localized prostate cancer
5